DK2859092T3 - Terapeutisk vaccine til behandling af diabetes type-1 hos børn, anvendelse af cellesorter og fremgangsmåde til at multiplicere treg-celler til fremstilling af terapeutisk vaccine til behandling af diabetes type-1 - Google Patents

Terapeutisk vaccine til behandling af diabetes type-1 hos børn, anvendelse af cellesorter og fremgangsmåde til at multiplicere treg-celler til fremstilling af terapeutisk vaccine til behandling af diabetes type-1 Download PDF

Info

Publication number
DK2859092T3
DK2859092T3 DK13739523.2T DK13739523T DK2859092T3 DK 2859092 T3 DK2859092 T3 DK 2859092T3 DK 13739523 T DK13739523 T DK 13739523T DK 2859092 T3 DK2859092 T3 DK 2859092T3
Authority
DK
Denmark
Prior art keywords
vaccine
therapeutic vaccine
behabete
multiplicating
children
Prior art date
Application number
DK13739523.2T
Other languages
English (en)
Inventor
Natalia Marek-Trzonkowska
Malgorzata Mysliwiec
Piotr Trzonkowski
Original Assignee
Gdanski Univ Medyczny
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gdanski Univ Medyczny filed Critical Gdanski Univ Medyczny
Application granted granted Critical
Publication of DK2859092T3 publication Critical patent/DK2859092T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/26—Lymph; Lymph nodes; Thymus; Spleen; Splenocytes; Thymocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/22—Immunosuppressive or immunotolerising
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/416—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N13/00—Treatment of microorganisms or enzymes with electrical or wave energy, e.g. magnetism, sonic waves
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C12N5/0637—Immunosuppressive T lymphocytes, e.g. regulatory T cells or Treg
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2302—Interleukin-2 (IL-2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/11—Coculture with; Conditioned medium produced by blood or immune system cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Rheumatology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
DK13739523.2T 2012-06-06 2013-06-04 Terapeutisk vaccine til behandling af diabetes type-1 hos børn, anvendelse af cellesorter og fremgangsmåde til at multiplicere treg-celler til fremstilling af terapeutisk vaccine til behandling af diabetes type-1 DK2859092T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PL399447A PL218400B1 (pl) 2012-06-06 2012-06-06 Szczepionka do leczenia cukrzycy typu 1 u dzieci, zastosowanie sortera komórek oraz sposób namnażania komórek Treg in vitro do wytwarzania szczepionki do leczenia cukrzycy typu 1
PCT/PL2013/000072 WO2013184011A1 (en) 2012-06-06 2013-06-04 Therapeutic vaccine for treatment of diabetes type 1 in children, application of the cell sorter and the method of multiplying treg cells to produce therapeutic vaccine for treatment of diabetes type 1

Publications (1)

Publication Number Publication Date
DK2859092T3 true DK2859092T3 (da) 2020-07-27

Family

ID=48808489

Family Applications (1)

Application Number Title Priority Date Filing Date
DK13739523.2T DK2859092T3 (da) 2012-06-06 2013-06-04 Terapeutisk vaccine til behandling af diabetes type-1 hos børn, anvendelse af cellesorter og fremgangsmåde til at multiplicere treg-celler til fremstilling af terapeutisk vaccine til behandling af diabetes type-1

Country Status (12)

Country Link
US (4) US20150165007A1 (da)
EP (1) EP2859092B1 (da)
CY (1) CY1123467T1 (da)
DK (1) DK2859092T3 (da)
ES (1) ES2807279T3 (da)
HR (1) HRP20201177T1 (da)
HU (1) HUE057439T2 (da)
LT (1) LT2859092T (da)
PL (2) PL218400B1 (da)
PT (1) PT2859092T (da)
SI (1) SI2859092T1 (da)
WO (1) WO2013184011A1 (da)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170232084A1 (en) 2013-04-26 2017-08-17 Enzo Biochem Inc. Immune modulation for the treatment of age-related macular degeneration
PL236046B1 (pl) 2015-12-17 2020-11-30 Gdanski Univ Medyczny Sposób namnażania in vitro limfocytów T regulatorowych CD4+ FoxP3+
MX2021013227A (es) * 2019-04-30 2022-01-06 Univ California Expansion ex-vivo sin microesferas de celulas t reguladoras humanas.
PL241050B1 (pl) * 2019-12-12 2022-07-25 Gdanski Univ Medyczny Zastosowanie limfocytów T regulatorowych jako leku w leczeniu stwardnienia rozsianego
EP3985105A1 (en) 2020-10-16 2022-04-20 Uniwersytet Gdanski Conditioned regulatory t cell population tregs with enhanced therapeutic potential, method for obtaining of conditioned tregs and the medical use of the tregs population
EP3985106A1 (en) 2020-10-16 2022-04-20 Uniwersytet Gdanski Conditioned regulatory t cell population with enhanced therapeutic potential, method for obtaining of regulatory t cell population and the medical use of regulatory t cell population
WO2025096685A1 (en) * 2023-10-30 2025-05-08 City Of Hope Methods of making and using regulatory t cells for treatment of autoimmune disorders and cancers
WO2025219454A1 (en) 2024-04-18 2025-10-23 Poltreg S.A. Preproinsulin tolerogenic fragments for treating and monitoring type 1 diabetes

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2527830A1 (en) 2003-06-02 2004-12-23 Mercia Pharma, Inc. Therapeutic vaccine compositions for the treatment of type 1 diabetes
JP2006280307A (ja) * 2005-04-01 2006-10-19 Kyoto Univ 制御性ｔ細胞の製造方法
US8916147B2 (en) * 2005-08-24 2014-12-23 Yeda Research and Devolpment Co. Ltd. Universal donor-derived tolerogenic cells for inducing non-syngeneic transplantation tolerance
WO2007117602A2 (en) * 2006-04-07 2007-10-18 Biogen Idec Ma Inc. Isolation and use of human regulatory t cells
WO2007127787A2 (en) * 2006-04-25 2007-11-08 Joslin Diabetes Center, Inc. Insulin autoantigen-specific regulatory cd4+ t cells
WO2010022341A1 (en) * 2008-08-21 2010-02-25 The United State Of America, As Represented By The Secretary, Department Of Health And Human Services Methods of enriching and using regulatory t cells
EP2402029A1 (en) 2010-07-01 2012-01-04 Sanofi Pasteur Enterovirus vaccines for preventing or treating type 1 diabetes (III)
EP2402028A1 (en) 2010-07-01 2012-01-04 Sanofi Pasteur Enterovirus vaccines for preventing and treating type 1 diabetes (II)
US9481866B2 (en) * 2011-12-16 2016-11-01 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods of producing T cell populations enriched for stable regulatory T-cells

Also Published As

Publication number Publication date
EP2859092A1 (en) 2015-04-15
US20180117134A1 (en) 2018-05-03
HRP20201177T1 (hr) 2021-02-19
HUE057439T2 (hu) 2022-05-28
WO2013184011A1 (en) 2013-12-12
PL2859092T3 (pl) 2020-11-16
PL218400B1 (pl) 2014-11-28
US20240197848A1 (en) 2024-06-20
SI2859092T1 (sl) 2021-02-26
CY1123467T1 (el) 2022-03-24
PL399447A1 (pl) 2013-12-09
PT2859092T (pt) 2020-07-23
US20200054724A1 (en) 2020-02-20
EP2859092B1 (en) 2020-04-29
US11944672B2 (en) 2024-04-02
US20150165007A1 (en) 2015-06-18
ES2807279T3 (es) 2021-02-22
LT2859092T (lt) 2020-09-25

Similar Documents

Publication Publication Date Title
DK2859092T3 (da) Terapeutisk vaccine til behandling af diabetes type-1 hos børn, anvendelse af cellesorter og fremgangsmåde til at multiplicere treg-celler til fremstilling af terapeutisk vaccine til behandling af diabetes type-1
IL285843A (en) Ibrutinib for use in the treatment of chronic graft versus host disease
IL244668A0 (en) Compositions and formulations for prevention and treatment of diabetes and obesity, and methods of production and use thereof in glucose and caloric control
DK2632954T4 (da) Midler og fremgangsmåder til behandling af dlbcl
DK2756073T3 (da) Manipuleret væv til in vitro-forskningsanvendelser, anordninger deraf og fremgangsmåder til fremstilling deraf
DK3088353T3 (da) Bilirubinpartikler og deres fremstilling til anvendelse i terapi
DK2815769T3 (da) Fam19a5 til anvendelse i diagnosticering og behandling af skader på centralnervesystemet
DK3546569T3 (da) Terapeutiske midler med anvendelse af fedtceller og cellesekreter
BR112014005355A2 (pt) células t de memória central anti-terceiro, métodos de produção e uso das mesmas em transplante e tratamento de doença
IL239923A0 (en) Solid solution compositions and use in cardiovascular disease
DK2894151T3 (da) Imidazolinderivater, fremgangsmåder til fremstilling deraf og anvendelse deraf i medicin
DK2931143T3 (da) Implantat og føring til kæbe-ansigts-kirurgi
DK2938740T3 (da) Kimære fgf19-peptider til anvendelse til behandling af galdesyrelidelser
DK3622883T3 (da) Indførerer til medicinsk indretning og fremgangsmåder til at indføre og anvende medicinske indretninger
DK2533747T5 (da) Apparat til behandling af en patient med vibrationsstimulationer, taktile stimulationer og/eller termiske stimulationer
DK3019483T3 (da) Terapeutiske aktive forbindelser og fremgangsmåder til deres anvendelse
HUE045629T2 (hu) Készítmények, alkalmazások és eljárások anyagcsere rendellenességek és betegségek kezelésére
DK4000608T3 (da) Farmaceutisk sammensætning, fremgangsmåder til behandling og anvendelser deraf
DK2858550T3 (da) Fremgangsmåde og apparat til at fremme administrationen af sundhed og sikkerhed
DK2555807T5 (da) Skabelon-øceller og små øcelleklynger til behandling af diabetes
LT2729151T (lt) Farmacinė kompozicija, gydymo būdai ir jų panaudojimas
DK2661494T3 (da) Promotorer, ekspressionskassetter og vektorer til anvendelse ved behandling af achromatopsi og andre sygdomme
HUE051632T2 (hu) Betegségek kezelésére szolgáló készítmények és eljárások
LT3730132T (lt) Kompozicija, skirta panaudoti pacientų su didele širdies ir kraujagyslių ligų rizika antsvorio ir nutukimo gydymo būde
HUE046671T2 (hu) Glutárimid származékokat tartalmazó gyógyászati készítmény, valamint ennek alkalmazása eozinofil betegségek kezelésében